Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹313.97B
Enterprise Value₹210.41K
Total Cash (Recent Filing)₹6.62B
Total Debt (Recent Filing)₹22.33B
Price to Earnings (P/E)76.8
Beta1.26
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.11
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Return To ProfitabilityA sustained revenue rebound (~12% in FY2026) and return to net profitability (~₹2.13B) strengthen the firm’s ability to internally fund operations and regulatory investments. Over the next 2–6 months this improves credibility with partners and reduces near-term refinancing pressure while supporting product investment.
Manageable Leverage And Stronger Equity BaseStable debt (₹20–24B) alongside a higher equity base (~₹49.4B) and rising total assets (~₹86.2B) provide balance-sheet cushioning. This durable improvement reduces solvency and refinancing risk, supports capital spending and regulatory compliance, and increases flexibility for strategic initiatives over upcoming quarters.
Diversified Pharma Business ModelMultiple revenue streams — branded formulations, generics, APIs and regulated-market exports — create structural resilience. Diversification helps smooth product-cycle volatility, enables margin uplift from regulated exports, and offers multiple avenues (including contract manufacturing) to scale revenues over the medium term.
Bears Say
Inconsistent Historical Profitability And Volatile MarginsMulti-year losses and large EBIT swings undermine earnings predictability and indicate structural margin instability. Without persistent cost or portfolio improvements, past volatility suggests profit recoveries could reverse, complicating long-term planning and partnerships that rely on consistent operating performance.
Weak And Volatile Free Cash Flow GenerationModest FCF (~₹0.64B) with a sharp decline and historically volatile cash conversion limits self-funding capacity for capex, R&D, or M&A. Persistent cash variability raises the likelihood of external financing needs and constrains durable investment in manufacturing or product registrations over the medium term.
Exposure To Regulatory Approvals And Generics CompetitionStructural reliance on regulatory approvals and competitive generics pricing can cap margins and access to higher-value markets. Inspections, delayed approvals, or pricing pressure in generics are enduring risks that can materially affect revenue mix and long-term margin sustainability absent durable differentiation or exclusive products.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹313.97B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Nov 09, 2026 which is in 84 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Aug 10, 2026. The company reported ₹6.523 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹6.523 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.36%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―